Clinical Trial Update: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating anti-pseudomonas IgY to prevent infections in cystic fibrosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• Anti-Pseudomonas IgY (IgY antibodies against Pseudomonas aeruginosa)

Snippet

Sponsor: Immunsystem AB | Conditions: Cystic Fibrosis, Infection | Phase 1, Phase 2 | Status: COMPLETED